Navigation Links
BellBrook Labs Seeking Partners to Accelerate Commercialization of Innovative HTS Assay Technologies
Date:11/20/2013

Madison, WI (PRWEB) November 20, 2013

BellBrook labs, an innovative developer of drug discovery tools, is seeking out collaborative scientific and commercial partners in cases where further development or commercialization of a technology is outside of the company’s core capabilities. The company develops technologies for both cellular and biochemical HTS assays. The company’s iuvo™ microchannel array platform, developed with expert engineering, microfluidic and microfabrication capabilities, is a line of unique microscale devices for miniaturization and automation of advanced cell models that are more representative of human physiology. The company’s Transcreener® HTS enzyme assays rely on proprietary immunodetection reagents to enable screening of thousands of different enzymes, including validated targets like kinases, as well as emerging targets like ATPases, GTPases, methyltransferases, and glycosyltransferases. The partnering portfolio includes cutting-edge drug discovery tools for chemotaxis assays, invasion assays, and assays for GPCR related targets. Two examples of technologies available for partnering are described below and detailed descriptions of the entire portfolio are available on BellBrook’s new Partnering webpage.

The CellWasher Plate is a multiwell plate with proprietary modifications to the wells that protect cells from liquid flow and enable the use of full immunocytochemistry protocols and other assays with multiple wash steps with greater than 90% retention of even the most non-adherent cells. Prototypes have been tested at Pharma and life science research companies, and are ready for final design optimization and full scale manufacturing.

BellBrook’s RGScreen assay is the only HTS -ready assay method for measuring Regulaor of G Protein Signaling (RGS) protein catalytic activity. The most direct way to detect RGS function is by measuring the increased GTPase activity of the associated Galpha protein. However, the GTPase activity of isolated Galpha proteins is limited by GDP dissociation, so RGS GAP activity cannot be measured using simple biochemical assays. Bellbrook’s novel RGScreen™ platform overcomes this kinetic constraint by using proprietary Galpha protein variants with altered GTP hydrolysis and GDP dissociation rates that enable detection of RGS GAP activity using the Transcreener® GDP Assay.

About BellBrook Labs. BellBrook Labs is a private, R&D driven company dedicated to accelerating drug discovery and biological research by providing innovative high throughput screening solutions for enzymes and phenotypic assays. The company’s products, including Transcreener® HTS enzyme assays and iuvo™ Microconduit Array plates are used by all of the major pharmaceutical companies and are available directly from BellBrook Labs or from their international distribution partners. For more information on any of these technologies or to discuss partnering opportunities, contact BellBrook Labs: @info.bellbrooklabs.com.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11345539.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. BellBrook Labs Launches New Turn Key Methyltransferase Assay Kit for Oncogenic Histone Methyltransferase EZH2
2. BellBrook Labs Launches Second Generation Transcreener EPIGEN Methyltransferase Assay to Acclerate Epigenetic Drug Discovery
3. BellBrook Labs and Tecan Offer Webinar on Screening Epigenetic Targets
4. BellBrook Labs Launches Four New Turn-Key Methyltransferase Assay Kits
5. BellBrook Labs and BMG Labtech to Offer Webinar on Integrated Platform for Screening Kinases and Methyltransferases
6. BellBrook Labs Strengthens Ties with Cambio for Distribution of Transcreener HTS Assays in the UK
7. Foundation For the NIH Joins NIH In Seeking Proposals to Study Sports-Related Brain Injuries
8. The BioVoyage Institute is seeking the help of corporations, organizations, institutions, communities and individuals to help with bioscience and biotechnology education
9. Quantum Cures Announces Breakthrough Approach for Researchers Seeking Cures for Orphan and Rare Diseases
10. Chemical Publishing Company Seeking Authors for Titles on Waste Water Treatment, Ion Exchange, Reverse Osmosis, and Water Management for Shale Formation Gas Drilling
11. Chemical Publishing Company Seeking Authors for Definitive Title on Hydraulic Fracturing or Shale Gas Fracturing Technology, Fracking and Natural Gas Recovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 23, 2016 , ... Supplyframe, the Industry Network for electronics ... Lab . Located in Pasadena, Calif., the Design Lab’s mission is to bring ... designed, built and brought to market. , The Design Lab is Supplyframe’s physical ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a ... designed, tuned and optimized exclusively for Okuma CNC machining centers at The International ... a collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):